Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 1997

View Archived Issues

Company Profile: Pentose

Vitamin D analogue undergoes phase I evaluation for osteoporosis

Company Profile: Cubist Pharmaceuticals

Astra Merck and P&G to develop OTC formulation of Prilosec for heartburn

Glaucoma diagnostic technology covered by U.S. patent

Bard to distribute ProCyte's wound care products

Neovascularization inhibitors from Tsumura Juntendo

Farnesyltransferase inhibitors claimed by Banyu

Dainippon discloses new H+/K+-ATPase inhibitors

Sumitomo synthesizes new series of ECE inhibitors

FA-70D: a new cathepsin inhibitor from Taiho

New dihydropyridine derivatives with cardiovascular activity from Mercian

Toa Eiyo discovers new anti-H. pylori agents

Burzynski's antineoplastons in phase II testing for multiple oncology indications

Singulair available in Mexico for asthma

Biora in-licenses new protein for dental applications

Phase II trial of Vasoflux begins in acute MI

La Jolla evaluates Toleragan compounds for xenotransplantation

Millennium/Pfizer antifungal collaboration expanded

LJP-394 binds to B-cells in lupus patients

Seragen reports preliminary results of pivotal CTCL study

LifeCell's ThromboSol to enter clinical feasibility study

Clinical evaluation of adenoviral-p53 gene therapy for prostate cancer begins

Antidiabetic drug research at Takeda

Indomethacin: antitumor activity and effects on telomerase

Z-103 as effective as sulfasalazine in rat model of colitis

First U.S. trials of Zemaphyte to begin

Once-daily tacalcitol vs. twice-daily calcipotriol for chronic plaque psoriasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...